Glucarpidase should soon be approved throughout Europe to treat methotrexate toxicity. The European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) recently recommended the ...
London, Jan. 14, 2022 (GLOBE NEWSWIRE) -- SERB and BTG Specialty Pharmaceuticals today announced that the European Commission has granted marketing authorisation for Voraxaze® (glucarpidase) to reduce ...
West Conshohocken, PA, Dec. 11, 2023 (GLOBE NEWSWIRE) -- BTG Pharmaceuticals, a SERB company, announces the presentation of the largest study to date of patients with high-dose methotrexate (HDMTX) ...
Methotrexate (MTX) is used to treat malignant and autoimmune disorders, while it also hurts testicular tissue leading to infertility. It has been shown that MTX induces testicular injury by producing ...
Please provide your email address to receive an email when new articles are posted on . Patients who received glucarpidase for acute kidney injury from methotrexate treatment had improved kidney ...
A major new study has found a method to identify people who may experience blood, kidney, or liver related side effects from methotrexate, the most commonly used immune-suppressing medicine with 1.3 ...
A prospective trial of prophylaxis and treatment (P+T) of acute tumor lysis syndrome (ATLS) with rasburicase (R) and nonalkaline hydration in children and adolescents (C+A) with intermediate- (Group B ...
Allogeneic stem cell transplantation for patients over age 65 with acute myelogenous leukemia and myelodysplastic syndrome. BCR-ABL kinase domain mutations and resistance in Ph+ acute lymphoblastic ...
An FDA-approved medication called glucarpidase could serve as an antidote to kidney toxicity in patients receiving the chemotherapy drug methotrexate (MTX), according to a new study. Using data from ...
An FDA-approved medication called glucarpidase could serve as an antidote to kidney toxicity in patients receiving the chemotherapy drug methotrexate (MTX), according to a new study by investigators ...
Despite being in the earliest stages of clinical research, the makers of the novel drug NovoBioJect are touting results from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results